Paper Details

  1. Home
  2. Paper Details

A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.

Author: HubenR P, MurphyG P

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study compared three treatments for 261 patients with metastatic prostate cancer: (1) diethylstilbestrol (DES) or orchiectomy, (2) the hormone buserelin, and (3) methotrexate plus DES or orchiectomy. While there was no significant difference in overall survival between the groups, the time without disease progression (PFS) was significantly longer for patients receiving DES/orchiectomy or methotrexate plus DES/orchiectomy compared to those receiving buserelin. The study concludes that DES/orchiectomy and methotrexate plus DES/orchiectomy are more effective in delaying disease progression compared to buserelin.
Paper Details　
Original Abstract of the Article :
From April 1983 to March 1985, 265 patients with newly diagnosed metastatic prostate cancer were randomized to one of three treatment protocols: (1) diethylstilbestrol (DES) or bilateral orchiectomy, (2) the leutinizing hormone-releasing hormone (LHRH) analog buserelin, or (3) methotrexate plus DES ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1097-0142(19881101)62:9<1881::aid-cncr2820620902>3.0.co;2-9

データ提供：米国国立医学図書館（NLM）

Treating Prostate Cancer: Navigating a Complex Desert

Prostate cancer is a common and challenging disease, and finding the most effective treatment is a crucial journey for patients. This study compares three treatment protocols for newly diagnosed patients with metastatic prostate cancer: (1) diethylstilbestrol (DES) or bilateral orchiectomy, (2) the LHRH analog buserelin, and (3) methotrexate plus DES or orchiectomy. The study found that while there was no significant difference in overall survival between the three groups, progression-free survival was significantly longer for patients receiving methotrexate plus DES/orchiectomy compared to buserelin.

Methotrexate: A Potential Shortcut on the Prostate Cancer Journey

The study found that the combination of methotrexate plus DES/orchiectomy offered a significant advantage in terms of progression-free survival compared to buserelin alone. This suggests that this combination therapy could provide a more effective and prolonged control of disease progression, potentially extending the period during which patients can live without experiencing tumor growth.

Choosing the Right Path in Prostate Cancer Treatment

This study, like a guidebook through a complex desert landscape, helps navigate the challenging terrain of prostate cancer treatment. The findings suggest that methotrexate plus DES/orchiectomy could be a valuable option for patients seeking to prolong disease-free survival. This research provides a vital resource for oncologists and patients making critical decisions about prostate cancer treatment.

Dr.Camel's Conclusion

The journey through prostate cancer treatment can be like navigating a vast and unforgiving desert. This research offers a valuable map, highlighting the potential of methotrexate plus DES/orchiectomy as a more effective option for extending progression-free survival. By understanding the different paths available, patients and their physicians can make informed decisions to navigate this challenging terrain with greater confidence and hope.

Date :
  1. Date Completed 1988-11-15
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

3139279

DOI: Digital Object Identifier

10.1002/1097-0142(19881101)62:9<1881::aid-cncr2820620902>3.0.co;2-9

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.